Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Uncertainty surrounds potential for Novo's Tresiba

Wed, 19th Dec 2012 18:17

(Adds details, analyst quote) By Shida Chayesteh COPENHAGEN, Dec 19 (Reuters) - As Danish group Novo Nordisk awaits final approvals for its new long-actingdiabetes drug Tresiba, a Reuters poll found a wide range offorecasts for sales of a drug meant to challenge its biggestrivals. Tresiba's annual peak sales were seen in an 8-100 billionDanish crown ($1.4-$17.7 billion) range in the poll of 18analysts. Forecasts by analysts from international banks saw thebiggest span, while those by Danish peers were more uniform. The highest estimate of 100 billion crowns in annual peaksales was given by Swedbank analyst Johan Unnerus. "It is probably towards the high end but that is my guess,"Unnerus said. The most optimistic analysts see Tresiba sales peakingalready in 2017, while those with the lowest estimates do notforecast this to happen before 2025. Novo Nordisk, the world's biggest insulin producer, hasestimated that Tresiba, which is the brand name for the activeingredient degludec, could become a blockbuster drug. A drug reaches blockbuster status when it generates morethan $1 billion in annual sales. Tresiba is central to Novo's aim of ending rival Sanofi's dominance of the long-acting insulin market. Itexpects to launch the new product in several European marketsearly next year, subject to final approval. Most analysts expect the U.S. Food and DrugAdministration(FDA) will approve the drug, as it has alreadybeen approved by regulators in Japan. Last month, an advisory panel to the FDA voted to recommendapproval of Tresiba, despite signals of possible cardiovascularrisk. The FDA rarely goes against its advisory panel'srecommendations when making its final decision. One of the reasons for the big span in the estimates is thatTresiba's sales are likely to continue to rise until anotherproduct takes over, said DNB analyst Rune Majlund Dahl. "Normally in the industry, we're talking about 10 yearsgenerally, which is when you hit a 'patent wall', but that isnot the case with diabetes products because we historically haveseen that sales just continue," Dahl said. "You would probably still have seen rising sales of Levemirif it were not for Tresiba," he added, referring to Novo's otherinsulin drug. "It gets a little difficult to estimate more than five yearsinto the future," said Jacob Thrane, analyst at S&P Capital IQ. "Especially when you can see there are a few things in thepipeline at the moment both at Lilly and GlaxoSmithKline, and we must not neglect that Sanofi is goodto keep up its Lantus (sales)," he added.($1 = 5.6458 Danish crowns) (Writing by Victoria Klesty; editing by Stephen Nisbet andLouise Heavens)
More News
26 Jul 2023 09:28

TOP NEWS: GSK raises annual guidance on quarterly earnings growth

(Alliance News) - GSK PLC on Wednesday upgraded its full-year guidance, after seeing a strong quarterly performance on the strength of segments like HIV and Vaccines.

Read more
26 Jul 2023 07:55

GSK lifts full-year guidance after 'excellent' Q2

(Sharecast News) - GSK lifted its full-year guidance on Wednesday after an "excellent" second quarter.

Read more
24 Jul 2023 08:25

GSK says HIV prevention drug recommended for marketing in Europe

(Alliance News) - GSK PLC on Monday said ViiV Healthcare's cabotegravir for HIV prevention has received a positive opinion by the European Medicines Agency for marketing authorisation.

Read more
24 Jul 2023 07:07

GSK's ViiV gets Europe nod for HIV prophylaxis

(Sharecast News) - Pharmaceuticals giant GSK announced on Monday that its majority-owned HIV specialist subsidiary ViiV Healthcare has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorisation for 'cabotegravir' long-acting (LA) injectable and tablets for HIV prevention.

Read more
22 Jul 2023 18:32

Bavarian Nordic ends RSV vaccine programme after poor trial results

July 22 (Reuters) - Denmark-based Bavarian Nordic said on Saturday it was ending its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventing lower respiratory tract disease.

Read more
14 Jul 2023 09:13

LONDON BROKER RATINGS: HSBC says 'buy' AstraZeneca but 'reduce' GSK

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
14 Jul 2023 07:56

LONDON BRIEFING: Burberry shines in China; ITV-All3Media deal unlikely

(Alliance News) - Stocks in London are expected to slip into the red at Friday's open, in a tepid conclusion to what has been a largely positive week for global equities, as the market prices in a lower peak for US interest rates.

Read more
13 Jul 2023 16:13

Sensodyne toothpaste-maker Haleon planning job cuts - The Guardian

July 13 (Reuters) - Haleon, the world's biggest standalone consumer health business, is planning to cut hundreds of roles in the UK and worldwide, the Guardian reported on Thursday.

Read more
10 Jul 2023 09:27

LONDON BROKER RATINGS: HSBC downgrades commercial property stocks

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
6 Jul 2023 15:46

UK dividends calendar - next 7 days

Friday 7 July 
Anglo-Eastern Plantations PLCdividend payment date
Associated British Foods PLCdividend payment date
Blackrock Frontiers Investment Trust PLCdividend payment date
Crystal Amber Fund Ltddividend payment date
Forterra PLCdividend payment date
Hill & Smith PLCdividend payment date
JPMorgan Global Growth & Income PLCdividend payment date
LXi REIT PLCdividend payment date
Restore PLCdividend payment date
S&U PLCdividend payment date
Titon Holdings PLCdividend payment date
Victorian Plumbing Group PLCdividend payment date
Warehouse REIT PLCdividend payment date
Whitbread PLCdividend payment date
WPP PLCdividend payment date
Monday 10 July 
Capital Gearing Trust PLCdividend payment date
Great Portland Estates PLCdividend payment date
Tuesday 11 July 
Emis Group PLCdividend payment date
Pets at Home Group PLCdividend payment date
Wednesday 12 July 
Assura PLCdividend payment date
LondonMetric Property PLCdividend payment date
M&C Saatchi PLCdividend payment date
Pharos Energy PLCdividend payment date
Renew Holdings PLCdividend payment date
Thursday 13 July 
BlackRock Latin American Investment Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Caffyns PLCex-dividend payment date
CMC Markets PLCex-dividend payment date
FirstGroup PLCex-dividend payment date
GSK PLCdividend payment date
Halma PLCex-dividend payment date
Invesco Bond Income Plus Ltdex-dividend payment date
JPMorgan Japan Small Cap Growth & Income PLCex-dividend payment date
Record PLCex-dividend payment date
Schroder UK Mid Cap Fund PLCex-dividend payment date
Shoe Zone PLCex-dividend payment date
Sirius Real Estate Ltdex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
Triad Group PLCex-dividend payment date
Wincanton PLCex-dividend payment date
XP Power Ltddividend payment date
Young & Co's Brewery PLCdividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
5 Jul 2023 09:34

LONDON BROKER RATINGS: UBS likes Pearson; Liberum cuts Naked Wine

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
4 Jul 2023 10:18

PRESS: Advil owner Haleon to explore sale of nicotine gum business

(Alliance News) - Haleon PLC is exploring a potential divestment of some smoking cessation products, including the Nicotinell brand of nicotine gum, patches and lozenges, according to a Bloomberg report on Tuesday.

Read more
30 Jun 2023 22:38

First trial over Zantac cancer claims set for November

June 30 (Reuters) - The first U.S. trial over claims that discontinued heartburn drug Zantac causes cancer is now expected to take place in California state court on Nov. 13, a lawyer for plaintiffs in the litigation said Friday.

Read more
29 Jun 2023 06:30

Sanofi says it's back to the drawing board on mRNA flu vaccines

June 29 (Reuters) - Sanofi said that trials show the currently available mRNA technology behind the most successful COVID-19 shots will not be effective against influenza and it is already working on a next generation of shots.

Read more
28 Jun 2023 16:18

GSK completes acquisition of chronic cough-focused Bellus Health

(Alliance News) - GSK PLC on Wednesday said it completed its acquisition of Quebec-based late-stage biopharmaceutical firm Bellus Health Inc for a total equity value of USD2.0 billion.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.